Teaser Image JMCP Cover Image Teaser Text This JMCP article analyzes the cost-effectiveness of brexanolone compared to SSRIs for postpartum depression. Findings indicate that brexanolone may serve as a cost-effective option over SSRIs. Tags (Topics): Cost-Effectiveness URL https://www.jmcp.org/doi/full/10.18553/jmcp.2020.19306 Primary Taxonomy Tag Formulary & Utilization Management